7-氟-4-喹唑啉酮 | 16499-57-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 7-氟-4-喹唑啉酮
• 中文别名: 4(3H)-喹唑啉酮,7-氟；4-氧-7-氟喹唑啉；7-氟喹唑啉-4(3H)-酮；7-氟-4-羟基喹唑啉；7-氟喹唑啉-4-醇
• 英文名称: 7-fluoro-3H-quinazolin-4-one
• 英文别名: 7-fluoroquinazolin-4(3H)-one；7-fluoroquinazolin-4-one；7-fluoro-4-quinazolinone；7-fluoro-3,4-dihydroquinazolin-4-one；7-Fluoroquinazolin-4(3H)-one
• CAS: 16499-57-3
• 化学式: C₈H₅FN₂O
• mdl: MFCD07689443
• 分子量: 164.139
• InChiKey: KCORZHJVTZIZFD-UHFFFAOYSA-N

物化性质

• 熔点：
  246.0 to 250.0 °C
• 沸点：
  293.3±42.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  储存条件：室温、密封保存，并确保环境干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Fluoro-1h-quinazolin-4-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Fluoro-1h-quinazolin-4-one
CAS number: 16499-57-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5FN2O
Molecular weight: 164.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-氟-4-喹唑啉酮 在 吡啶 、 四氮唑 、 盐酸 、 氯化亚砜 、 N,N-二甲基乙酰胺 、 三氟乙酸五氟苯酯 、 氧化环己烯 、 sodium hydride 、 potassium iodide 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.17h， 生成 5-[[7-[3-[乙基[2-(磷酰氧基)乙基]氨基]丙氧基]-4-喹唑啉基]氨基]-N-(3-氟苯基)-1H-吡唑-3-乙酰胺
  参考文献：
  名称：

  新型吡唑并喹唑啉类化合物作为极光B激酶的选择性抑制剂的发现，合成和体内活性。

  摘要：

  作为开发新的抗癌剂的靶标，极光激酶已成为引起人们极大兴趣的主题。尽管有证据表明抑制Aurora B激酶会引起更明显的抗增殖表型，但迄今为止，据报道，临床上最先进的药物通常同时抑制Aurora A和B。我们发现了一系列吡唑并喹唑啉，其中有些显示超过1000倍在重组酶分析中对Aurora B的选择性高于Aurora A激酶活性。这些化合物已被设计用于肠胃外给药，并由于其以易于活化的磷酸酯衍生物形式传递的能力而实现了高水平的溶解性。前药在体内被完全转化为脱磷酸形式，并且活性物质具有有利的药代动力学性质和安全药理学特性。这些化合物具有惊人的体内活性，已经选择了化合物5（AZD1152）进行临床评估，目前处于1期临床试验中。

  DOI：

  10.1021/jm061335f
• 作为产物：
  描述：

  4-氟-2-硝基苯甲酸 在 吡啶 、 5%-palladium/activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 30.0~100.0 ℃ 、100.0 kPa 条件下， 反应 18.0h， 生成 7-氟-4-喹唑啉酮
  参考文献：
  名称：

  ARYLQUINAZOLINES

  摘要：

  这项发明涉及公式（I）的新化合物，可用于抑制丝氨酸-苏氨酸蛋白激酶，并使癌细胞对抗癌药物和/或电离辐射敏感化。

  公开号：

  US20160083401A1

文献信息

• An alternative synthesis of the non-small cell lung carcinoma drug afatinib
  作者：Tatjana Kovacevic、Milan Mesic、Amir Avdagic、Miroslav Zegarac

  DOI：10.1016/j.tetlet.2018.10.026

  日期：2018.11

  Afatinib (BIBW2992) is the anticancer drug developed by Boehringer Ingelheim. This work is reporting the synthesis of the afatinib using a new route by Ullmann-Goldberg reaction from corresponding 4-anilinoquinazoline iodide as the last step in the synthesis. This route was not described previously and it could be used for synthesis of afatinib analogues.

  阿法替尼（BIBW2992）是勃林格殷格翰公司开发的抗癌药物。这项工作报告了通过Ullmann-Goldberg反应从相应的4-苯胺基喹唑啉碘化物通过Ullmann-Goldberg反应的新路线合成afatinib的最后一步。该路线先前未作描述，可用于合成阿法替尼类似物。
• [EN] QUINAZOLINE COMPOUNDS<br/>[FR] COMPOSES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2004058752A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a sulphur atom and optionally containing one or more nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有硫原子并且可选地含有一个或多个氮原子的5-成员杂芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• [EN] PHOSPHONOOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DERIVES DE PHOSPHONOOXY QUINAZOLINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2004058781A1

  公开（公告）日：2004-07-15

  Quinazoline derivatives of formula (I) wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.

  式(I)中的喹唑啉衍生物，其中A是含有一个氮原子和一个或两个进一步氮原子的5-成员杂环芳基；含有它们的组合物，其制备方法以及它们在治疗中的用途。
• Synthesis and biological evaluation of a new class of quinazolinoneazoles as potential antimicrobial agents and their interactions with calf thymus DNA and human serum albumin
  作者：Li-Ping Peng、Sangaraiah Nagarajan、Syed Rasheed、Cheng-He Zhou

  DOI：10.1039/c4md00281d

  日期：——

  A series of novel quinazolinone azoles were synthesized and characterized by NMR, IR, MS and HRMS spectra. Bioactive assays showed that some target compounds exhibited significant antimicrobial potency. Especially, nitroimidazole derivative 3a displayed comparable or even superior antibacterial efficacies (MIC = 0.03–0.05 μmol mL−1) in contrast with norfloxacin (MIC = 0.01–0.05 μmol mL−1) and chloromycin

  一系列小说 喹唑啉酮合成了吡咯并通过NMR，IR，MS和HRMS光谱进行了表征。生物活性分析表明，某些目标化合物具有显着的抗菌效力。尤其是，硝基咪唑衍生物3a的抗菌效果与MIC相当，甚至更高（MIC = 0.03-0.05μmolmL -1）。诺氟沙星（MIC = 0.01–0.05μmolmL -1）和氯霉素（MIC = 0.02–0.10μmolmL -1）。通过紫外线可见光谱对化合物3a与小牛胸腺DNA进行的初步互动研究表明，化合物3a可以通过嵌入模式与DNA结合形成化合物3a –DNA复合物，并进一步阻止DNA复制，从而发挥强大的抗菌和抗真菌活性。氢键和范德华力在化合物3a –HSA的缔合中起重要作用。
• Platelet ADP receptor inhibitors
  申请人：Scarborough Robert M.

  公开号：US06906063B2

  公开（公告）日：2005-06-14

  Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

  化合物的结构式（I）至（VIII），特别包括磺酰脲衍生物、磺酰硫脲衍生物、磺酰胍衍生物、磺酰氰胍衍生物、硫代酰基磺酰胺衍生物和酰基磺酰胺衍生物，这些衍生物是有效的血小板ADP受体抑制剂。这些衍生物可用于各种药物组合物中，特别适用于预防和/或治疗心血管疾病，尤其是与血栓形成相关的疾病。本发明还涉及一种用于预防或治疗哺乳动物血栓形成的方法，包括给予化合物的结构式（I）至（VIII）或其药学上可接受的盐的治疗有效量。